Search

Displaying results 2791 - 2800 of 10000 in total
  1. Drug

    Risankizumab

    go.drugbank.com/drugs/DB14762
    ApprovedInvestigational

    [L39885] It gained its first global approval in Japan in March 2019, followed by approval in Canada, the US, and Europe in April 2019. … [A254716] Risankizumab is used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease.[L39885,L44191,L44231] Risankizumab is being investigated for atopic dermatitis.[A254716]

  2. Drug

    N-acetyltyrosine

    go.drugbank.com/drugs/DB11102
    ApprovedInvestigational

    N-acetyltyrosine is administered as parenteral nutrition or intravenous infusion due to its enhanced solubility compared to tyrosine [A32652]. … N-acetyltyrosine, also referred to as N-acetyl-L-tyrosine, is used in place of as a tyrosine precursor. [DB00135] is a non-essential amino acid with a polar side group.

    Mixtures: AMINOPLASMAL-5% E INFUSION, AMINOPLASMAL-10% E INFUSION
  3. Drug

    Prussian blue

    go.drugbank.com/drugs/DB06783
    Approved

    It was also administered in individuals exposed to 137-Cs+ during Goiânia accident, one of the worst radioactive contamination incidents that occured in Brazil, 1983. … Prussian blue is included in the World Health Organization Model List of Essential Medicines as a specific antidote used in poisonings to provide symptomatic and supportive treatment.

  4. Drug

    Rocuronium

    go.drugbank.com/drugs/DB00728
    ApprovedInvestigational

    It is commonly marketed under the trade names Zemuron and Esmeron. The drug is associated with the risk of developing allergic reactions in some high-risk patients, such as those with asthma. … [Sugammadex] is a γ-cyclodextrin derivative that has been introduced as a novel agent to reverse the action of rocuronium.

    Products: BROMURO DE ROCURONIO 50 MG/5ML., BROMURO DE ROCURONIO 25MG/2.5ML
  5. Drug

    Apomorphine

    go.drugbank.com/drugs/DB00714
    ApprovedInvestigational

    Apomorphine is a non-ergoline dopamine D2 agonist indicated to treat hypomobility associated with Parkinson's. It was first synthesized in 1845 and first used in Parkinson's disease in 1884.

    Synonyms: (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol, (R)-5,6,6a,7-tetrahydro-6-methyl-4H-dibenzo[de,g]quinoline-10,11-diolCategories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome, Serotonin Receptor Antagonists
  6. Drug

    Rimexolone

    go.drugbank.com/drugs/DB00896
    ApprovedWithdrawn

    It is used to treat inflammation in the eye. It is marketed as Vexol.

    Categories: Corticosteroid Hormone Receptor Agonists
  7. Drug

    Talimogene laherparepvec

    go.drugbank.com/drugs/DB13896
    ApprovedInvestigational

    The drug subsequently uses the melanoma cells' own machinery to multiply, eventually overwhelming the melanoma cells and killing them [L2221]. … It was approved by the FDA in 2015 under the market name Imlygic. In general, talimogene laherparepvec has been modified so that it can infect and multiply inside melanoma cells [L2221].

    Synonyms: T Vec, T-Vec
  8. Drug

    Revefenacin

    go.drugbank.com/drugs/DB11855
    ApprovedInvestigational

    Revefenacin is a novel biphenyl carbamate tertiary amine agent that belongs to the family of the long-acting muscarinic antagonists (LAMA). … The labile primary amide in the structure produces a "soft-drug" site that allows rapid systemic clearance and minimizing of the systemically mediated adverse reactions.

  9. Drug

    Lomitapide

    go.drugbank.com/drugs/DB08827
    Approved

    Unlike traditional statin therapy, which relies on the upregulation of LDL receptors to clear cholesterol, Lomitapide acts independently of the LDL receptor by preventing the assembly and secretion of … [A275445, A7367] This makes it a critical therapeutic option for "receptor-negative" patients who have little to no functional LDL receptor activity.

  10. Drug

    Nonacog beta pegol

    go.drugbank.com/drugs/DB13933
    ApprovedInvestigational

    Once activated, the activation molecule with PEG is cleaved to leave the activated factor IX (Factor IXa). … [A31496] Nonacog beta pegol was developed by Novo Nordisk and received its first global approval by the FDA on May 31, 2017,[L1098] followed by the European Commission approval on June 2, 2017.

    Products: REFİXİA 500 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR, REFİXİA 1000 IU ENJEKSİYONLUK ÇÖZELTİ HAZIRLAMAK İÇİNTOZ VE ÇÖZÜCÜ , 1 ADET FLAKON + 1 ADET ÇÖZÜCÜ İÇEREN KULLANIMA HAZIR ENJEKTÖR